568 related articles for article (PubMed ID: 27558232)
1. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
2. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
Salem AH; Agarwal SK; Dunbar M; Nuthalapati S; Chien D; Freise KJ; Wong SL
J Clin Pharmacol; 2016 Nov; 56(11):1355-1361. PubMed ID: 27029823
[TBL] [Abstract][Full Text] [Related]
3. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
5. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia.
Salem AH; Dunbar M; Agarwal SK
Anticancer Drugs; 2017 Sep; 28(8):911-914. PubMed ID: 28562380
[TBL] [Abstract][Full Text] [Related]
7. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects.
Cheung TT; Salem AH; Menon RM; Munasinghe WP; Bueno OF; Agarwal SK
Clin Pharmacol Drug Dev; 2018 May; 7(4):435-440. PubMed ID: 29058801
[TBL] [Abstract][Full Text] [Related]
13. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
16. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax for the treatment of patients with chronic lymphocytic leukemia.
Crombie J; Davids MS
Future Oncol; 2017 Jun; 13(14):1223-1232. PubMed ID: 28492339
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
Minocha M; Zeng J; Medema JK; Othman AA
Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
